NVO250103C115000
- 0.01
- 0.000.00%
Novo-Nordisk A/S Newsroom
Why Did Novo Nordisk (NVO) Go Down on Friday?
Trending Stocks as Wall Street Bounces Back With Strong Week
Top Gap Ups and Downs on Friday: NVO, UBS, IBN and More
These Stocks Moved the Most Today: Apple, Alphabet, Qorvo, Novo Nordisk, SLB, J.B. Hunt, Rivian, and More -- Barrons.com
Novo-Nordisk A/S Options Spot-On: On January 17th, 93,932 Contracts Were Traded, With 417.48K Open Interest
Sector Update: Health Care Stocks Decline Late Afternoon
Novo Nordisk Unusual Options Activity
European stock markets have risen for the fourth consecutive week, with the FTSE 100 Index outperforming.
European stock markets have risen for four consecutive weeks, with mining stocks increasing, following reports that Rio Tinto and Glencore are discussing a merger of businesses. The United Kingdom stock market has reached a record high. The Stoxx Europe 600 Index closed up 0.7%, led by mining stocks. The FTSE 100 Index rose by 1.4%, achieving its best three-day increase since 2022, with the largest exporters benefiting from the weakness of the British Pound. Medical Care is the only sector in the European stock indices that declined, as Novo-Nordisk A/S fell following reports that the Ozempic and Wegovy weight loss drugs are targets for Insurance price negotiations. The decline in the pharmaceutical company's stock price caused its Market Cap to fall below that of the Luxury Goods leader.
Nvidia, Smucker, Muni Bonds, and 31 Other -6-
The king of Luxury Goods returns: LVMH surpasses Novo-Nordisk A/S, reclaiming the top spot in Europe's Market Cap.
①LVMH's market value surpasses Novo-Nordisk A/S, regaining the title of the most valuable Listed in Hong Kong company in Europe; ②LVMH's stock price fell 13% last year, but signs of Industry recovery and positive earnings reports from peers have raised expectations, leading analysts at Bank of America to upgrade LVMH's rating to 'Buy'; ③Novo-Nordisk A/S is affected by multiple factors including supply and Pharmaceutical pricing concerns, an increasingly competitive environment, and disappointing results from experimental drug trials.
Hims & Hers Health Down 3% After BoA Says Q4 Revenue Could Be a Miss
European Equities Traded in the US as American Depositary Receipts Edge Higher Friday
EU Panel Starts Probe on Novo Nordisk Weight Loss Drugs' Links to Rare Eye Disease
Novo Nordisk's Positive Obesity Drug Data Insufficient to Buoy Shares -- Market Talk
Argus Research Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating
4 Stocks to Watch on Friday: SLB, NVO and More
Novo Nordisk's Ozempic, Wegovy Among Drugs Chosen for US Medicare Price Talks
Pre-market drop of over 4%! Novo-Nordisk A/S's "weight loss miracle drug" enters price negotiations with USA healthcare.
The diabetes drug Ozempic and the weight loss drug Wegovy, among 15 other medications from Novo-Nordisk A/S, have been included in the USA government’s plan for Medicare price negotiations scheduled for 2027. After this announcement, Novo-Nordisk A/S's stock price was surpassed by LVMH, making it the second largest publicly traded company in Europe.
White House Says Popular Weight-loss Drug Ozempic Subject to Medicare Talks
These Stocks Are Moving the Most Today: Apple, Qorvo, Novo Nordisk, Fastenal, J.B. Hunt, Rivian, Salesforce, and More -- Barrons.com